A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

Phase 2

Completed

• Conditions: Molluscum Contagiosum
• Interventions: Drug: SB206 8%; Drug: SB206 12%; Drug: Placebo; Drug: SB206 4%

• Registration Number: NCT03436615
• Lead Sponsor: Novan, Inc.

Brief Summary

This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.

Detailed Description

This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in up to approximately 192 or 256 non-immunocompromised subjects with molluscum contagiosum. Subjects who satisfy entry criteria will be randomized 3:1 to ascending, sequential dose cohorts of SB206. The highest tolerated dose will also be run in a cohort once daily. Approximately 64 subjects will be randomized to each cohort. Subjects will be treated once daily, twice daily or three times a week for up to 12 weeks. After 30 subjects randomized in a cohort have completed 2 weeks of treatment, the Data Safety Monitoring Board (DSMB) will review the available unblinded safety and tolerability data. The DSMB will determine if the data supports escalating to the next highest dose for the next cohort or if the data shows the dose is not tolerable decreasing to the next lower dose or frequency for the next cohort.

Study Timeline

• Study Start: 2018-01-24
• Study First Submitted: 2018-02-06
• Study First Submitted QC: 2018-02-12
• Study First Posted: 2018-02-19
• Primary Completion: 2018-11-03
• Study Completion: 2018-11-03
• Disposition First Submitted: 2019-09-09
• Results First Submitted: 2023-01-23
• Status Verified: 2023-04
• Results First Submitted QC: 2023-04-10
• Last Update Submitted: 2023-04-10
• Results First Posted: 2023-05-06
• Disposition First Posted: 2023-05-06
• Last Update Posted: 2023-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 256

Inclusion Criteria

• Be 2 years of age or older, and in good general health;
• Have signed written informed consent form by a parent or legal guardian (assent form where required);
• Have between 3 and 70 MC at baseline, excluding periocular (within 2 cm circumference of the eye) and lesions on the labia and penis;
• Females 10 years of age and older must have a negative urine pregnancy test prior to randomization;
• Females 10 years of age and older must agree to use an effective method of birth control during the course of the study and for 30 days after their final study visit;
• Be willing and able to follow study instructions and likely to complete all study requirements.

Exclusion Criteria

• Are immunosuppressed, have immunodeficiency disorder, or are on immunosuppressive treatment;
• Have agminated MC that could make it difficult to provide accurate lesion counts;
• Have active atopic dermatitis with intense erythema and/or excoriations, that impact currently or could impact at any point during the study the ability to count MC lesions;
• Have significant eczematous reactions or other skin disease surrounding MC that may impact the ability to count lesions;
• Have received treatment with topical calcineurin inhibitors or steroids on MC or within 2 cm of MC lesions within 14 days prior to baseline;
• Have received treatment for MC during the 14 days prior to baseline with podophyllotoxin, imiquimod, cantharidin, sinecatechins, topical retinoids, oral or topical zinc, or other homeopathic or OTC products including, but not limited to, Zymaderm and tea tree oil, cimetidine and other histamine H2 receptor antagonists;
• Have received surgical procedures (cryotherapy, curettage, other) within 28 days prior to baseline;
• Have MC only in periocular area;
• Have MC only on the labia or penis;
• Female subjects who are pregnant, planning a pregnancy or breastfeeding;
• Have confirmed methemoglobin level of >3.0% at Baseline using a pulse co-oximeter;
• Have know hypersensitivity to any ingredients of SB206 or Vehicle Gel including excipients;
• Have participated in a previous study with NVN1000;
• Have participated in any other trial of an interventional investigational drug or device within 30 days or concurrent participation in another interventional research study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
SB206 8%	SB206 8%	SB206 8% topically twice daily
SB206 12%	SB206 12%	SB206 12% topically once or twice daily
Placebo (vehicle gel)	Placebo	Vehicle Gel topically once or twice daily
SB206 4%	SB206 4%	SB206 4% topically twice daily

Primary Outcome Measures

Name	Time	Method
Proportion of Subjects Achieving Complete Clearance at Week 12	12 weeks	Percent (proportion) of subjects with complete clearance of all treatable MC at Week 12. This was measured by dividing the number of subjects who showed complete clearance by the number in that treatment group (this represents our primary outcome variable).

Secondary Outcome Measures

Name	Time	Method
Proportion of Subjects Achieving Complete Clearance at Each Visit	Week 1; Week 2; Week 4; Week 8; Week 12	Proportion of subjects achieving complete clearance of all treated molluscum contagiosum lesions at each visit.
Time to First Complete Clearance	Week 12	Median time to reach first complete clearance of all molluscum contagiosum lesions (Kaplan-Meier estimate)
Proportion of Subjects Achieving 75% Reduction at Each Visit	Week 1, Week 2, Week 4, Week 8, Week 12	Proportion of subjects achieving 75% reduction from baseline in number of molluscum contagiosum at each visit
Mean Change in Molluscum Contagiosum at Each Visit	Week 1, Week 2, Week 4, Week 8, Week 12	Mean change from baseline in number of molluscum contagiosum lesions at each visit
Percent Change in Molluscum Contagiosum at Each Visit	Week 1, Week 2, Week 4, Week 8, Week 12	Percent change from baseline in number of molluscum contagiosum lesions at each visit

Trial Locations

Locations (18)

Premier Site# 264; 🇺🇸 Doral, Florida, United States

Premier Site# 252; 🇺🇸 Norman, Oklahoma, United States

Premier Site# 253; 🇺🇸 Lenexa, Kansas, United States

Premier Site# 167; 🇺🇸 Houston, Texas, United States

Premier Site# 255; 🇺🇸 Mount Pleasant, South Carolina, United States

Premier Site# 256; 🇺🇸 Salt Lake City, Utah, United States

Premier Site# 266; 🇺🇸 Scottsdale, Arizona, United States

Premier Site# 257; 🇺🇸 Thornton, Colorado, United States

Premier Site# 116; 🇺🇸 Newnan, Georgia, United States

Premier Site# 251; 🇺🇸 Indianapolis, Indiana, United States

Premier Site# 237; 🇺🇸 Gresham, Oregon, United States

Premier Site# 131; 🇺🇸 Houston, Texas, United States

Premier Site# 224; 🇺🇸 San Antonio, Texas, United States

Premier Site# 267; 🇺🇸 Richmond, Virginia, United States

Premier Site# 117; 🇺🇸 Louisville, Kentucky, United States

Premier Site# 260; 🇺🇸 Santa Ana, California, United States

Premier Site# 182; 🇺🇸 Las Vegas, Nevada, United States

Premier Site# 259; 🇺🇸 Charleston, South Carolina, United States